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The genetic regulatory signature of type 2 diabetes
in human skeletal muscle
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Type 2 diabetes (T2D) results from the combined effects of genetic and environmental
factors on multiple tissues over time. Of the4100 variants associated with T2D and related
traits in genome-wide association studies (GWAS), 490% occur in non-coding regions,
suggesting a strong regulatory component to T2D risk. Here to understand how T2D status,
metabolic traits and genetic variation influence gene expression, we analyse skeletal muscle
biopsies from 271 well-phenotyped Finnish participants with glucose tolerance ranging from
normal to newly diagnosed T2D. We perform high-depth strand-specific mRNA-sequencing
and dense genotyping. Computational integration of these data with epigenome data,
including ATAC-seq on skeletal muscle, and transcriptome data across diverse tissues reveals
that the tissue-specific genetic regulatory architecture of skeletal muscle is highly enriched in
muscle stretch/super enhancers, including some that overlap T2D GWAS variants. In one
such example, T2D risk alleles residing in a muscle stretch/super enhancer are linked to
increased expression and alternative splicing of muscle-specific isoforms of ANK1.
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T
he prevalence of diabetes in 2015 reached 415 million
adults worldwide, and is projected to increase to 642
million by 2040 (www.idf.org/diabetesatlas). T2D accounts
for B90% of these individuals1. Pancreatic islet beta-cell
dysfunction, accentuated by insulin resistance in skeletal muscle
and other peripheral tissues, are the hallmarks of T2D2.
To examine the relationship between T2D and related traits
and muscle metabolism, we obtained blood samples and skeletal
muscle biopsies, and performed clinical phenotyping, including
oral glucose tolerance tests (OGTT), on 271 Finnish individuals.
Study subjects were chosen to span the range of glucose tolerance
from normal to newly diagnosed (not on glucose-lowering
drug therapy) T2D.
Because most (490%) T2D and related trait GWAS
single-nucleotide polymorphisms (SNPs) reside in non-coding
regions, we aim to refine the molecular mechanisms underlying
these associations by identifying the target gene(s) and direction
of effect the risk allele has on target gene expression. To
accomplish this, we further perform dense and diverse molecular
profiling on this collection of skeletal muscle biopsies at the
genome, epigenome and transcriptome level. Integration of these
data types allowed us to nominate multiple T2D GWAS SNP
effector transcripts. These genetic, epigenomic and transcriptomic
results represent the largest study of the regulatory landscape in
human muscle and reveal how it relates to T2D.
Results
T2D insights from mRNA-seq maps and clinical phenotypes.
We sequenced the mRNA from study participants (Fig. 1a,
Supplementary Table 1) to a mean depth of 91.3M strand-specific
paired-end reads, the most comprehensive human skeletal muscle
transcriptome catalogue to date3–5. We tested for (1) differential
gene expression between individuals with T2D and normal glucose
tolerance (NGT) and (2) association between gene expression and
three T2D-related traits (fasting glucose, fasting insulin and body
mass index (BMI)) (Fig. 1b), adjusting for covariates (see
Methods). At a false discovery rate (FDR) of 5%, we found three
genes differentially expressed with T2D status; most strongly
differentially expressed was a positive regulator of senescence,
ubinuclein 1 (UBN1) (b¼ 0.83, q-value¼ 0.0089). At FDR 5%, we
detected a wide range in the number of gene–trait associations,
from 38 for fasting glucose to 6,080 for fasting insulin.
To probe the underlying biology of differential gene expression,
we performed gene ontology (GO) term analysis for each
trait using the strength and direction of trait–gene association
( log10(P value) signed for the direction of association) as a
predictor of GO term membership6. We display a pruned list
of the most strongly associated GO terms, selected separately
for terms enriched for genes with positive and negative trait
association (Fig. 1c, Supplementary Fig. 1).
With T2D status, and with increases in fasting glucose, fasting
insulin and BMI, we observed lower expression of genes involved
in endoplasmic reticulum protein localization and translational
elongation. For T2D, the most significant trends were for
decreased expression of cellular respiration genes (q-value¼ 1.4
 10 35), consistent with previous observations in skeletal
muscle samples from T2D and NGT individuals following
hyperinsulinemic–euglycemic clamp7. Mitochondrial regulatory
protein PGC-1alpha (PPARGC1A) was identified by Mootha
et al.7 as a potential master regulator of mitochondrial expression.
We observed lower, non-significantly different expression levels
of PPARGC1A (b¼  0.24, q-value¼ 0.57) in individuals with
T2D. Decreased mitochondrial function is a component of the
mTOR pathway which is dysregulated in metabolic diseases;
downregulation of the pathway shifts cells away from protein
synthesis and cell growth and towards protein catabolism8.
Consistent with this, for T2D, we observed lower expression of
genes involved in generation of precursor metabolites,
translational elongation and higher expression of genes involved
in protein polyubiquitination (Fig. 1c).
Interestingly, higher expression levels of genes for leucocyte
activation were strongly associated with higher levels of fasting
insulin (q-value¼ 1.3 10 14) and less strongly with other
traits. This could suggest that muscle samples from individuals
with insulin resistance have increased inflammatory cell
infiltration. However, this association remained when we
estimated and then adjusted for the fraction of white blood cells
(WBCs) and lymphocytes in the muscle samples (see Methods) in
the trait–gene expression analysis (q-value¼ 2.5 10 14,
Supplementary Fig. 2).
Genetic and epigenomic regulatory architecture of muscle. To
understand how genetic variation may influence muscle gene
expression and thus T2D and related traits, we successfully
genotyped 267 of the 271 samples using the Illumina Omni2.5
array and imputed 8,406,237 SNPs with minor allele frequency
40.01 using the Genetics of Type 2 Diabetes (GoT2D) reference
panel (Methods). We tested for association of variants within
1Mb of the transcription start site (TSS) with gene expression
(cis-eQTL). At FDR¼ 5%, we detected 2,104,118 cis-eQTLs in
19,697 (92%) of 21,420 tested genes (Supplementary Table 2), of
which 168,633 cis-eQTLs remained when pruned on a per-gene
basis by linkage disequilibrium (LD) at r2o0.2. cis-eQTLs cluster
at the TSS (Supplementary Fig. 3), as previously noted9,10. Within
15,449 tested protein-coding genes, 14,479 (93.6%) had Z1 cis-
eQTLs. Using a complementary approach, we tested for allele-
specific expression (ASE) in protein-coding genes that had a
heterozygous-transcribed SNP in Z10 individuals; we detected
ASE at FDR¼ 5% in 7,404 (80.2%) of 9,228 tested genes (see
Supplementary Fig. 4 for overlap with cis-eQTL). We compared
the total set of our cis-eQTL results to those of 361 genotype-
tissue expression (GTEx)5 skeletal muscle samples for 95.5M
SNP–gene pairs tested in both studies (Supplementary Fig. 5). Of
these SNP–gene pairs, in our muscle sample at FDR¼ 5% we
detected 3.5M SNP–gene pairs, of which 83.8% had a concordant
direction in GTEx. Comparing our catalogue to the 1.1M GTEx
SNP–gene pairs (FDR¼ 5%), 813K SNP–gene pairs were
significantly associated in both studies; 99% of these had
concordant effect directions.
Previous studies of blood and lymphoblastoid cell lines have
shown enrichment of cis-eQTLs that overlap enhancer and
promoter regions9,10. To explore this relationship in muscle, we
created chromatin state maps using ChromHMM11 for skeletal
muscle and 30 diverse cell or tissue types, including adipose, liver
and pancreatic islets (Supplementary Fig. 6; see Methods). To
assess the relationship between our skeletal muscle cis-eQTLs and
chromatin states, we calculated enrichment statistics for how these
different features overlap while controlling for minor allele
frequency, distance to TSS and the number of SNPs in LD12.
We observed enrichment of skeletal muscle cis-eQTLs in genomic
regions with active (promoter, enhancer or transcribed) chromatin
states and a depletion in those with inactive (low signal) chromatin
states across a broad range of cell types (Fig. 2a). This general
enrichment pattern may reflect the predominance of cis-eQTLs
from widely expressed housekeeping genes and mask a smaller set
of muscle-specific genes.
To develop a measure of muscle gene expression specificity, we
analysed additional RNA-seq data representing a set of diverse
tissues from the Illumina Human Body Map 2.0 project. We used
an information theory approach13,14 to score genes based on
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muscle expression level and specificity relative to the panel of 16
diverse tissues; we refer to this score as the muscle expression
specificity index (mESI; Methods) (Fig. 2b). We divided the genes
into mESI deciles, where the 1st decile represents genes that are
expressed at uniformly low levels across all tissues and the 10th
decile represents genes that are highly and specifically expressed
in muscle (Fig. 2c). cis-eQTL SNPs for genes in the 10 deciles
were collected and partitioned into corresponding bins, which
showed a larger range in skeletal muscle chromatin state
enrichments (Supplementary Fig. 7) compared with the general
non-mESI-based enrichments (Fig. 2a).
We previously defined chromatin ‘stretch enhancers’ as long
(Z3 kb) regions of tissue-specific active chromatin, and found
they are highly enriched for GWAS variants in disease-relevant
tissues15,16. Here we observed increasing cis-eQTL enrichment
with increasing mESI decile in skeletal muscle stretch enhancers,
but neither in muscle ‘typical enhancers’ (r800 bp; median
enhancer size) nor in stretch and typical enhancers from other
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Figure 1 | Molecular profiling maps of skeletal muscle combined with dense phenotyping reveals insights about T2D. (a) To understand the full
spectrum of genetic variation and regulatory element usage in T2D-relevant tissue and across disease progression, we obtained skeletal muscle biopsies
from the vastus lateralis of 271 well-phenotyped Finnish individuals with normal and impaired glucose tolerance, impaired fasting glucose or newly
diagnosed, untreated T2D. (b) Correlogram of Spearman rank correlation coefficients for key metabolic traits. (c) Heatmap of GO terms for differentially
expressed genes. For each trait, the 20 GO terms most significantly enriched for positive expression–trait association and the 20 GO terms most
significantly enriched for negative expression–trait association were selected. GO terms were pruned to eliminate redundant terms. The terms were
hierarchically clustered using the GO term enrichment beta. Darker red, stronger positive gene expression–trait association; darker blue, stronger negative
association. Circle size represents number of significant GO terms.
NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11764 ARTICLE
NATURE COMMUNICATIONS | 7:11764 |DOI: 10.1038/ncomms11764 | www.nature.com/naturecommunications 3
tissues (Fig. 2d, Supplementary Fig. 8). Enrichment remained at
different length thresholds (longest 10, 5, 1%) for calling stretch
enhancers (Supplementary Fig. 9). Super enhancers17,18, defined
based on the abundance of acetylated lysine 27 on histone H3
(ref. 19), substantially overlap stretch enhancers (Supplementary
Fig. 10) and show similar muscle cis-eQTL enrichment trends
(Supplementary Fig. 11). These results suggest that the genetic
regulatory architecture of muscle-specific gene expression is
preferentially encoded in muscle stretch/super enhancers relative
to typical enhancers.
Regulatory information encoded in DNA is activated through
the binding of transcription factors (TFs) that can alter
nucleosomal architecture and increase local chromatin
accessibility. Because the stretch and super enhancer maps are
based on modified histone data sets, it is difficult to detect these
local TF-binding events. To construct higher-resolution
regulatory maps across skeletal muscle and specifically within
the larger stretch enhancer regions, we performed open
chromatin accessibility mapping in frozen skeletal muscle using
ATAC-seq20. We found that ATAC-seq performed on frozen
skeletal muscle is reproducible using 10 and 2mg tissue inputs
(Fig. 3a, Supplementary Fig. 12), and therefore we combined
these replicates for further analyses. Comparison of our skeletal
muscle ATAC-seq maps with similar maps from adipose21, the
lymphoblastoid cell line GM12878 (ref. 20), and with our
chromatin states at the ANK1 locus revealed striking muscle-
specific chromatin architecture that is consistent with the
chromatin state maps (Fig. 3a, orange-highlighted region). For
example, the skeletal muscle ATAC-seq peak calls occur
preferentially at skeletal muscle promoter and enhancer
chromatin states. Applying this analysis genome wide, we found
a high degree of correspondence between the peak calls
and active chromatin states (Fig. 3b). When considering only
TSS-distal (45 kb away from a TSS) ATAC-seq peaks, the
overlap with skeletal muscle strong enhancer chromatin states is
the highest across all tissues (Fig. 3b, Supplementary Fig. 13).
To obtain an even higher-resolution regulatory map, we
performed TF-binding site (TFBS) footprinting analyses, using
the CENTIPEDE algorithm22. This analysis predicts TF binding
based on the occurrence of a motif and the pattern of ATAC-seq
transposition events surrounding it. To detect motif occurrences
that could be altered by the presence of alleles not in the reference
genome, we used a SNP-aware motif scanning approach
(see Methods). We detected high-quality footprints for the
ubiquitous transcriptional insulator CCCTC-binding factor
(CTCF) and the tissue-specific regulator MYOD (Fig. 3c), in
addition to many other factors (see Methods). Notably, at
nucleosome-size distances adjacent to the CTCF footprint regions
we observe phased spikes in the ATAC-seq signal (Fig. 3c,
left column middle row), consistent with the known nucleo-
some-phasing properties of CTCF23.
The collection of ATAC-seq peaks and TFBS footprints define
progressively smaller regions within muscle stretch enhancers
(Fig. 3d), and these regions are progressively more enriched to
overlap cis-eQTL at increasing mESI deciles (Fig. 3e).
Collectively, these results demonstrate the high quality of our
frozen skeletal muscle ATAC-seq data and help to refine the
location of transcriptional regulatory variation, suggesting that
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Figure 2 | The genetic regulatory architecture of muscle-specific gene expression. (a) Muscle cis-eQTL enrichment across chromatin states in diverse
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index (mESI) decile 10; genes which are lowly and ubiquitously expressed fall in decile 1. (c) As mESI decile increases, genes have greater expression in
skeletal muscle but not in other tissue types. (d,e) cis-eQTL genes stratified by mESI decile. cis-eQTLs which fall into muscle stretch enhancers (Z3 kb) are
significantly enriched for genes expressed highly and specifically in muscle versus cis-eQTLs in typical enhancers (r800bp).
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such maps can be used to identify potentially causal TFBSs that
drive cis-eQTL signals.
Linking GWAS SNPs to effector transcripts in muscle. We and
others previously demonstrated that stretch/super enhancers in
disease-relevant tissues are highly enriched for GWAS-disease-
associated SNPs15,19, and a recent study identified autoimmune
GWAS SNPs that reside in a T-cell super enhancer and act as
cis-eQTL24. However, no T2D GWAS cis-eQTLs in stretch/super
enhancers have been identified in any tissues. To identify genetic
regulatory signatures that may contribute to the diabetes
phenotype, we assessed the overlap of our muscle cis-eQTL
catalogue with 225 GWAS SNPs associated with T2D and 7n T2D-
related traits (see Methods). Of the 220 GWAS SNPs assessed in
our study, 99 SNPs in 218 GWAS SNP–gene pairs (of a total 4,545
GWAS SNP–gene pairs) had Z1 significantly associated genes.
We performed iterative conditional analysis to identify GWAS cis-
eQTL SNPs likely to be independent of SNPs with substantially
stronger expression associations in the same gene (see Methods).
53 variants in 78 GWAS SNP–gene pairs (59 unique genes)
remained associated (FDR o5% for the conditional analysis); of
these 38 of the 53 variants remained after pruning at r2o0.2. The
top conditional cis-eQTL signals for GWAS SNPs are shown in
Table 1; the full list is shown in Supplementary Data 1.
We observed a top T2D GWAS SNP cis-eQTL signal for the
muscle-specific (mESI decile¼ 10) gene ANK1 (Fig. 4a), where
the T2D risk allele at rs516946 resulted in increased gene
expression (Table 1). Although the underlying molecular
mechanisms were unknown at the time, this locus was first
reported as being associated with T2D25,26, the results we present
here help define the impact on skeletal muscle gene expression.
This cis-eQTL SNP resides in a skeletal muscle stretch/super
enhancer (Fig. 4b,c, Supplementary Fig. 14). Notably, there are no
amino-acid-altering variants in strong LD (r2Z0.8) with
rs516946, but several overlap active chromatin marks in skeletal
muscle tissue and human skeletal muscle myoblast (HSMM) cells
(Supplementary Fig. 15). One such SNP, rs508419, is flanked by
skeletal muscle stretch enhancers, resides in an active promoter
specific to skeletal muscle and HSMM, and overlaps an
ATAC-seq peak in our muscle data (Fig. 4c). This active
promoter ATAC-seq peak SNP is immediately upstream of the
TSS for highly expressed short isoforms of ANK1 (Fig. 4b, see
inset bar plot) and is predicted by our SNP-aware motif scans to
disrupt a TR4-binding site, consistent with what is reported in the
HaploReg database27.
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We tested each allele of rs508419 in an electrophoretic mobility
shift assay (EMSA) using nuclear extract from human skeletal
muscle cells (SkMC). We found that the non-risk allele is
preferentially bound compared with the risk allele (Fig. 4d). This
allelic effect was replicated in both human (HSMM) and mouse
(C2C12) myoblast cells (Supplementary Fig. 16). Our ATAC-seq
footprinting results indicate that TR4 is bound at this position
(CENTIPEDE posterior probability¼ 1), and we observe an
allele-specific supershift in the EMSA using a TR4 antibody
(Fig. 4d). Together, these results suggest that TR4 binding at the
non-risk allele is linked to transcriptional repression, consistent
with previous reports about TR4 activity28,29, and that TR4
binding and repression is disrupted by the T2D risk allele at
rs508419, which results in increased ANK1 expression.
Further splicing (sQTL) and exon usage (exonQTL) investigation
(see Methods) of the muscle mRNA-seq data revealed complex
splicing patterns that are not apparent when considering bulk gene
expression. sQTL analysis of the four short ANK1 isoforms with a
TSS near the active muscle promoter rs508419 SNP (Fig. 5a) showed
that abundance for two of the isoforms (ENST00000522543.1 and
ENST00000314214.8) is significantly affected by rs508419
genotype, whereas the other two (ENST00000457297.1 and
ENST00000522231.1) appear to be invariant (Fig. 5b,c). Interest-
ingly, the two variable transcripts change expression by rs508419
T2D risk allele copies in opposite directions: ENST00000522543.1
decreases expression while ENST00000314214.8 increases it
(Fig. 5c). We confirmed this sQTL analysis using an independent
exonQTL analysis, quantitative reverse transcription–PCR and
droplet digital PCR (ddPCR) (Supplementary Figs 17–20).
Discussion
Protein products of the small ANK1 isoforms we identified as
linked to a T2D GWAS SNP through our skeletal muscle cis-eQTL
map interact with obscurin30,31, a critical component of, and
required for, proper sarcoplasmic reticulum (SR) assembly32,33.
The SR is involved in insulin action on glucose uptake through the
regulation of GLUT4 translocation to the plasma membrane
(reviewed in ref. 34). Recently, ANK1 was shown to interact with
IRS1 in skeletal muscle35. IRS1 is indispensable in insulin action on
glucose uptake in human SkMCs36. Thus, ANK1 is linked to
glucose uptake in muscle, and alterations to its expression might
perturb this process leading to an insulin-resistant state.
However, how the different small ANK1 isoforms influence
insulin-stimulated glucose uptake is presently unclear. Functional
studies to better characterize this process are needed.
In summary, we report here on a genome-wide genetic and
mRNA-seq analysis of the largest set of clinically characterized
human muscle samples described to date. We observed lower
expression in T2D individuals for genes involved with cellular
respiration, consistent with a previous smaller study7. We
demonstrated that the genetic regulatory architecture of
muscle-specific gene expression is highly and specifically
enriched in muscle stretch/super enhancers. We identified T2D
and related trait GWAS SNPs as cis-eQTLs for several genes,
including complex transcriptional and splicing regulation of the
muscle-specific isoforms of ANK1 that is associated with SNPs
that reside within a muscle stretch enhancer. Together, these
studies define links between GWAS SNPs and their target genes
in skeletal muscle, providing functional insights with potential
precision therapeutic implications for T2D.
Methods
Sample recruitment. We attempted to contact still-living FUSION spouses and
offspring who participated in FUSION study visits between 1994 and 1998 (ref. 37),
individuals who had participated in the population-based Savitaipale Prospective
Diabetes Study38, the FINRISK 2007 survey, the Dose Responses to Exercise
Training (DR’s EXTRA) study39 and the Metabolic Syndrome in Men (METSIM)
Table 1 | Detection of independent genic cis-eQTLs associated with T2D and related traits.
GWAS locus
gene name*
GWAS
trait (s)*
GWAS
SNP*
GWAS risk/
higher trait
level allele*
GWAS OR/
effect size*,w
eQTL
effect
sizez
eQTL
gene
MESI
deciley
eQTL
q-value
eQTL
conditional
q-value||
ERAP2 2-h glucose rs1019503 A 0.063 1.16 ERAP2 3 2.1 1062 7.0 10 84
ERAP2 2-h glucose rs1019503 A 0.063 0.97 LNPEP 7 8.1 10 36 7.8 10 39
ERAP2 2-h glucose rs1019503 A 0.063 0.90 CTD-2260A17.2 7 1.1 10 28 4.4 10 33
AMT Fasting glucose rs11715915 C 0.012 0.61 AMT 1 1.3 10 10 5.8 10 32
ANK1 T2D rs515071 C 1.18 1.01 ANK1 10 1.9 10 19 2.0 10 24
ANK1z T2D rs516946 C 1.09 1.01 ANK1 10 1.9 10 19 2.0 10 24
FADS1, FADS1-2-3 Fasting glucose rs174550 T 0.022 0.77 FADS1 3 4.2 10 18 3.2 10 20
POU5F1/TCF19 T2D rs3132524 G 1.07 0.84 CCHCR1 9 4.2 10 17 1.2 10 19
POU5F1/TCF19 T2D rs3132524 G 1.07 0.79 HCG27 2 4.6 10 15 1.9 10 14
AMT Fasting glucose rs11715915 C 0.012 0.68 NICN1 5 1.6 10 13 1.4 10 13
JAZF1 T2D rs849135 G 1.11 0.38 JAZF1 4 5.3 104 5.6 10 11
KCNJ11 T2D rs5215 C 1.07 0.33 ABCC8 NA 1.5 10 2 1.4 10 10
GPSM1 T2D rs11787792 A 1.15 0.38 GPSM1 1 1.9 10 3 6.7 10 10
PROX1 Fasting glucose rs340874 C 0.021 0.49 PROX1-AS1 3 1.3 10 6 7.5 10 10
PROX1 T2D rs340874 C 1.07 0.49 PROX1-AS1 3 1.3 10 6 7.5 10 10
ZFAND3 T2D rs9470794 C 1.12 0.90 ZFAND3 9 5.1 108 1.4 10 9
2-h, 2 hour; eQTL, expression quantitative trait locus; GWAS, genome-wide association studies; SNP, single-nucleotide polymorphism; T2D, type 2 diabetes; TSS, transcription start site.
T2D and related trait GWAS and candidate gene-associated variants were tested for association with genes whose most distal TSS was within 1Mb of the variant.
*We use GWAS to denote GWAS or candidate gene studies.
wT2D odds ratio (OR) or trait effect size for GWAS risk or higher trait level allele.
zeQTL effect for GWAS risk or higher trait level allele.
yDecile 10 denotes most muscle-specific expression, NA denotes insufficient expression in the Illumina Body Map tissues to estimate specificity.
||15 most significant conditional cis-eQTL results (for the 4,545 tested GWAS-SNP–gene pairs) that also have an cis-eQTL q-valueo0.05 (genome-wide).
zSee Supplementary Data 1 for ANK1 SNP rs515071 (high r2 with rs516946).
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study40. Additional subjects were recruited by newspaper advertisements. We
excluded individuals: (1) with drug treatment for diabetes, (2) with diseases that
might be expected to confound the analyses (for example, cancer, skeletal muscle
diseases, acute or chronic inflammatory diseases), (3) with diseases that increase
haemorrhage risk during biopsy (for example, von Willebrand’s disease,
haemophilia, severe liver diseases), (4) taking medications that need to be taken
daily and increase haemorrhage risk in the biopsies including warfarin (patients on
acetosalicylic acid were instructed to stop for 7 days prior to biopsy), (5) taking
medications that could confound the analyses (for example, oral corticosteroids,
other anti-inflammatory drugs such as 5-ASA, infliximab or methotrexate), and (6)
of ageo18 years. The study was approved by the coordinating ethics committee of
the Hospital District of Helsinki and Uusimaa. A written informed consent was
obtained from all the subjects.
Clinical visit. We performed clinical visits in Helsinki, Savitaipale and Kuopio. 279
individuals participated in both clinical and muscle biopsy visits
(see below). The clinical visit included a 2-h, four-point OGTT and other
phenotypes measured after a 12-h overnight fast, and health history, medication
and lifestyle questionnaires. The clinical visit took place for an average of 14 days
before the biopsy visit (90% of clinical visitsr32 days before biopsy; range 89 days
before to 15 days after). We defined glucose tolerance categories of NGT, impaired
glucose tolerance (IGT), impaired fasting glucose (IFG) and T2D using World
Health Organization (WHO) criteria41.
Phenotype measurements and laboratory analysis. We measured height and
weight in light clothing. Waist circumference was measured midway between the
lower rib margin and the iliac crest. We determined OGTT plasma glucose
(fluoride citrate plasma) concentrations by hexokinase assay (Abbott Architect
analyzer, Abbott Laboratories, Abbott Park, IL, USA) and serum insulin by
chemiluminescent microparticle immunoassay (Architect analyzer). Glucose and
insulin analyses were done at a certified core laboratory at the National Institute for
Health and Welfare, Helsinki, Finland.
Muscle biopsy visit. Biopsies were performed using a standardized protocol and
one physician (T.A.L.) trained all doctors performing biopsies. We instructed
participants to avoid strenuous exercise for at least 24 h prior to biopsy. Following
overnight fast, we obtained B250mg vastus lateralis skeletal muscle using a
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Figure 4 | T2D GWAS SNPs in a muscle-specific stretch enhancer of ANK1 provide mechanistic insights into T2D pathophysiology in skeletal muscle.
(a) Regional association plot showing the significance of SNPs (points) associated with expression of ANK1 (highlighted with red rectangle), where the best
cis-eQTL rs516946 (purple point) is a T2D GWAS SNP. (b) UCSC genome browser view of chromatin states near ANK1 isoforms. The chromatin states
between skeletal muscle and other T2D relevant cell types (adipose, liver, islets) are markedly different. ANK1 is associated with hereditary spherocytosis, a
disease of the red blood cells, which is consistent with the transcribed chromatin states in K562, a myelogeneous leukaemia line of the erythroleukemia
type. T2D and related trait GWAS SNPs (dark green) and SNPs in strong LD (r2Z0.8; blue) are found within muscle-specific stretch enhancers. ANK1
expression is shown for each isoform and normalized so that the sum over all isoforms is 1. (c) The chromatin states across T2D relevant tissues or cells for
SNPs in strong LD (r2Z0.8) with T2D GWAS SNP rs516946. Location of the ATAC-seq peak is noted. Asterisks denote SNPs that reside in stretch (Z3 kb)
enhancers. Colour-coding of chromatin is as shown in b. (d) EMSA using human skeletal muscle cell (SkMC) nuclear extract demonstrates allele-specific
binding (see lower horizontal arrow on the left side of the gel) for the non-risk allele (A) of rs508419. A supershift (see upper horizontal arrow on the left
side of the gel) using the TR4 antibody shows that TR4 participates in the allele-specific binding.
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conchotome, under local anesthesia with 20mgml 1 lidocaine hydrochloride
without epinephrine. Altogether 9 experienced and well-trained physicians collected
331 muscle biopsies in 2009–2013 in 3 different study sites (Helsinki, Kuopio and
Savitaipale). Three physicians, one in each site, performed most of the biopsies (237).
All physicians were trained to perform the biopsy in an identical manner. The
muscle samples were cleaned of blood, fat and other non-muscle tissue by scapel and
forceps, rinsed with NaCl 0.9% solution, and frozen in liquid nitrogen. Samples were
frozen within 30 s after sampling. Muscle samples were then stored at  80 C for a
duration of 0–4 years before analysis. Overall, the biopsy procedure was well-tol-
erated. Apart from a few expected cases of bruising, numbness at the biopsy site and
vasovagal reactions, there were no clinically significant adverse sequelae.
RNA isolation and mRNA sequencing. We visually dissected 30–50mg of each
frozen muscle biopsy sample to avoid adipose tissue. Total RNA was extracted and
purified with Trizol (Invitrogen, Carlsbad, CA). RNA integrity numbers ranged
from 7.2 to 9.4 (median 8.5). To minimize and quantify batch effects, we randomly
queued samples for sequencing using a 24-sample barcode-pooling approach and
targeted proportional representation of the OGTT states (NGT, IGT, IFG and
T2D) in each sequencing batch. External RNA Controls Consortium (ERCC) RNA
controls were spiked prior to barcoding to facilitate library quality control (QC).
Poly(A)-selected RNA samples were sequenced by the NIH Intramural Sequencing
Center (NISC) using the Illumina TruSeq directional mRNA-seq library protocol
to a targeted depth of 480 million 100 bp paired-end reads per sample. In total,
279 samples and 7 technical replicates were sequenced in 3,386 read groups on 164
lanes using 6 different HiSeq sequencing machines.
mRNA-seq processing and QC. We retained RNA-seq reads passing the Illumina
chastity filter and mapped reads to a reference sequence composed of ERCC
control fragments and all chromosomes and contigs from hg19, excluding alternate
haplotypes, replacing chromosome M with the Cambridge Reference Sequence and
masking the pseudoautosomal region on chromosome Y. We aligned reads using
STAR (version 2.3.1y)42 with default parameters and a splice junction catalogue
based on Gencode v19 (ref. 43). Duplicate read pairs were retained. Non-uniquely
mapping reads and read pairs with unpaired alignments were discarded.
RNA-seq QC was performed at the level of read groups (that is, a library on a
lane) using QoRTs44. We inspected the comprehensive set of QC metrics generated
by QoRTs for outlying libraries, lanes and sequencing runs. We additionally used
the 92 ERCC RNA spike-in controls and in-house scripts to assess library quality
and batch effects, and to check the accuracy of the strand-specific protocol45. This
process revealed one outlying library for insert size and a second library with gene
body coverage skewed towards the 30 end, possibly indicating RNA degradation.
Both of these libraries were removed from further analyses.
Inspection of read counts revealed systematic batch effects for the proportion of
reads mapping to the mitochondrial genome, with up to 52% mitochondrial reads
in some sequencing batches. We examined library degradation within affected
batches by inspecting gene body coverages for individual highly expressed
single-isoform genes and ERCC spike-in transcripts. This did not show any
evidence of RNA degradation, but did reveal the presence of systematic batch
effects with patterns of read coverage heterogeneity along genes or spike-in
transcripts, typically highly similar within batches with noticeable systematic
differences between some batches. This result strongly suggests we can correct for
these in downstream analyses. Further analysis revealed that batches with high-
mitochondrial read fractions had lower estimated RNA fragment lengths.
To address variability in mitochondrial read fraction, we calculated fragments
per kilobase transcript per million mapped reads (FPKMs) separately for nuclear
genes, mitochondrial genes and ERCC transcripts. PCA on the nuclear genome
FPKM matrix and colour labelling by sequencing batch also revealed the presence
of systematic batch effects. PCA on the ERCC spike-in FPKM matrix recapitulated
these batch effects. In our primary trait-gene expression association analysis, we
correct for these observed batch effects. In the cis-eQTL analyses, we correct for
these observed batch effects, as well as unknown technical confounders, by using
the PEER framework46. PCA after PEER correction effectively removed batch
effects (Supplementary Fig. 21). We further investigated possible technical
confounders in mRNA-seq by checking for sample-specific GC-content biases,
which have been reported in early RNA-seq studies. We found no evidence for
such effects in our data.
We used verifyBamID47 to check for sample swaps and contamination. We
asked if reads in the RNA-seq BAM files matched the SNP chip genotype data in
transcribed regions for each individual, and determined whether BAM files were
contaminated and comprised of reads derived from more than one individual. We
identified two pairs of sample swaps which we were able to correct; one of these
samples had an estimated contamination of 8% and was excluded. As an additional
check for sample swaps and to detect outliers, we verified reported sex by
examining expression of the XIST gene and mean Y chromosome gene expression.
PCA on the FPKM matrix identified four samples as outliers; they were removed
from further analyses. One additional sample was an outlier with respect to age
(20 years) and was excluded. After all QC exclusions, 271 samples remained and
were used for trait-associated expression analyses; of these, 267 had genotype data
available and were used for cis-eQTL analyses.
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Expression quantification. To study a wide spectrum of regulatory variation, we
performed analyses at three levels: gene, exon and transcript. Definitions for all
transcriptome features were based on GENCODE v19 (ref. 43). We counted
fragments mapping to genes using htseq-count v0.5.4 (ref. 48) (http://www-huber.
embl.de/users/anders/HTSeq/doc/count.html) and calculated FPKM values for each
gene. For differential expression analysis and cis-eQTL mapping, we filtered for
genes with five or more counts in Z25% of samples. We counted reads in exonic
parts of genes using dexseq_count v1.0.2 (ref. 49) and calculated exon-level FPKMs
for all transcripts in the GENCODE v19 comprehensive annotation. To avoid
double-counting of fragments in the quantification of exon abundance, we clipped
overlapping read pair mates using the ClipOverlap function of BamUtil
(http://genome.sph.umich.edu/wiki/BamUtil:_clipOverlap). We estimated transcript
abundance using rSeq (http://www-personal.umich.edu/Bjianghui/rseq/) which is
based on a Poisson regression model50. This model uses information from the insert
length distribution inferred using the aligned read fragments which has been shown
to help improve estimation. To reduce the number of transcripts per gene to avoid
identifiability issues and to restrict analysis to high-confidence transcripts, we
estimated transcript expression values for the subset of GENCODE transcripts with
the tag ‘basic’ in the GTF file.
Trait–gene expression association. We use ‘trait’ to refer to T2D status or a
related quantitative trait. First, we describe trait–gene expression analyses with
adjustment for known covariates. Second, we describe an analysis that also includes
adjustment for unknown factors learned from the gene expression data. Our primary
analysis was without adjustment for unknown factors since we were concerned that
the unknown factors might include biological signal, as well as expression differences
due to technical issues. We compare the results of the two analyses.
T2D–gene expression association. For individual i and gene j, let Ti denote T2D
status {0¼NGT, 1¼T2D} and Zi¼ {Z1,Z2,y.,ZC}T the vector of c covariates. Let
Yij, denote the rank-based inverse normalized FPKMij where inverse normalization
is performed for each gene, randomly breaking ties. We tested for association
between Yij and T2D status using the linear regression model:
Yij ¼ aj þ bjTi þ gTj Zi þ eij ð1Þ
where aj is the intercept, bj is the regression coefficient for T2D status on gene j, gj a
vector of coefficients for the covariates and eij is a normally distributed error term
with mean 0 and variance s2. We included as covariates age, sex and experimental
batch.
Quantitative trait–gene expression association. To define a transformed
quantitative trait Xi, we (1) inverse normalized the raw quantitative trait, (2)
adjusted for age, sex and experimental batch by linear regression, and (3) inverse
normalized the resulting residuals. To define the gene expression value, Yij, for each
gene we (1) inverse normalized FPKMij, (2) performed linear regression of age, sex
and experimental batch on the inverse normalized FPKMij and (3) inverse nor-
malized the resulting residuals. We then tested for association between transformed
gene expression Yij and each transformed quantitative trait Xi using linear
regression model:
Yij ¼ ajþ bjXiþ eij ð2Þ
where bj is the regression coefficient for Xi on gene j.
We used FDR51 to account for multiple testing and considered as significant
associations with FDRr5%.
Association analysis adjusting for unobserved confounders. To examine the
effect of potential unobserved technical confounders on gene expression–trait
association, we modified our definition of transformed gene expression Yij by (1)
inverse normalizing FPKMij (2) performing factor analysis via PEER46,52 on the
inverse normalized FPKMs specifying from 1 to 15 factors, together with covariates
age, sex and experimental batch, and (3) inverse normalizing the residuals. We
used the transformed Yij to perform differential expression analysis for each trait as
above for T2D (equation (1)) and quantitative traits (equation (2)). For each trait,
we selected the number of factors that maximized the number of differentially
expressed genes. We ran GO term analysis and compared the results to those
obtained without adjustment (see below)
Association analysis adjusting for tissue heterogeneity. The presence of non-
muscle cells/tissue within the muscle biopsies may influence the trait and quan-
titative trait-expression analysis. To investigate this, we estimated tissue hetero-
geneity, via tissue deconvolution analysis, using the DeconRNASeq R package
(v1.8.0)53. As a reference transcriptome panel, we used skeletal muscle, adipose,
WBC and lymph node transcriptomes from Illumina Body Map 2.0, randomly
subsampling reads to an equal amount and calculating FPKMs. For each reference
tissue, we calculated the expression specificity index (see below) of each gene and
selected the top 500 tissue-specific genes per tissue to use as the reference set. Using
the combined tissue-specific gene set, we estimated the tissue heterogeneity of each
skeletal muscle biopsy sample. In our samples, we estimated o0.1% adipose
contamination, 9–27% WBC, 0–18% lymphocyte and 64–86% skeletal muscle
across samples.
To adjust for the effects of non-muscle tissue, we included the estimated
percentages of WBCs and lymph as additional covariates in our trait and
quantitative trait-expression analysis. We ran GO term analysis and compared the
results with those obtained without adjustment (Supplementary Fig. 2).
GO term enrichment analysis. For each trait, we performed GO term enrichment
analysis using RNA-Enrich6. For each trait, we define P as the signed-log10
(trait–gene expression P value), signed as ‘þ ’ for trait–gene expression association
in which higher values of gene expression are associated with T2D, and ‘ ’ for
lower gene expression associated with T2D. We used the logistic regression model
log itðpjÞ ¼ aþ bPj þ gLj ð3Þ
where pj is the probability of GO term membership for gene j, a is the intercept, b
is the regression coefficient for association of GO term membership with P, the
signed –log10(P value), and g is the regression coefficient for the GO term
membership with L, the log10(gene length). We include L in the model to account
for the potential confounding effect of gene length on the enrichment test; longer
genes tend to have higher power for expression–trait association, and many GO
terms contain set of genes that are substantially longer or shorter than average.
To present the GO term results, for each of the 4 traits tested we retained the 20
most statistically significant GO terms in which genes showed positive association
with the trait and the 20 most significant GO terms in which genes showed
negative association with the trait. Within each trait and direction of association,
we ranked the GO terms from 1 (most significant) to 20. We combined the
40 4¼ 160 GO terms and assigned the lowest rank when GO terms appeared
more than once on the list. We pruned redundant GO terms from the combined
lists of GO terms, preferentially retaining GO terms with lower ranks54. We
hierarchically clustered the pruned GO terms based on the regression coefficients
(b’s) from equation (2) from the four traits using complete linkage and the
Euclidean distance measure in four-dimensional space.
To assess the robustness of our findings, we repeated RNA-Enrich6 analysis
using the PEER factor adjusted trait–gene expression association results (see
above). Results were very similar.
Sample and genotype QC. We extracted DNA from blood. DNA samples were
genotyped at the Genetic Resources Core Facility (GRCF) of the Johns Hopkins
Institute of Genetic Medicine on the HumanOmni2.5-4v1_H BeadChip array
(Illumina, San Diego, CA, USA). We mapped the Illumina array probe sequences
to the hg19 genome assembly using the Burrows-Wheeler Aligner (BWA)55. We
excluded SNPs with probe alignment problems, known variants in the 30 end of
probes, call rates o95%, minor allele count (MAC) o1 or Hardy–Weinberg
equilibrium P value o10 6, leaving 1,642,012 SNPs for subsequent analysis. All
alleles were oriented relative to the reference.
Of the 271 individuals that passed RNA-seq QC, we genotyped 267 samples, of
which all were successful, with minimum call rate 498.7%. Based on 10 duplicate
samples (from a larger set of genotyped samples), overall genotype concordance
was 99.993%. We identified two unexpected pairs of first-degree relatives using
KING (http://people.virginia.edu/Bwc9c/KING/). Each was an NGT-IGT pair;
from each pair we excluded the NGT participant. We performed principal
components analysis using SMARTPCA56 on 156,416 SNPs with MAF45% and in
near linkage equilibrium (r2o0.2), after excluding SNPs from regions of high LD57.
No population outliers were identified.
Imputation. We performed SNP imputation using a two-step strategy58. As
reference panel we used the haplotypes from 2,737 European individuals sequenced
in the GoT2D project. To improve phasing quality given the small target sample
set, we pre-phased our 267 individuals together with the GoT2D reference panel
samples using ShapeIT version 2 (https://mathgen.stats.ox.ac.uk/genetics_software/
shapeit/shapeit.html). We then imputed genotypes with Minimac2 (ref. 59). For
chromosome X, we performed pre-phasing and imputation separately for the
pseudo-autosomal and non-pseudo-autosomal regions. For cis-eQTL analysis, we
included 8,406,237 variants with imputation quality r240.3 and MAC45.
cis-eQTL analysis. We performed cis expression quantitative trait (eQTL) analysis
of SNPs within 1Mb of the most upstream TSS of each gene using Matrix eQTL60,
separately at the levels of gene, exon and transcript isoforms. To generate the gene
expression value Yij, we (1) inverse normalized FPKMji (2) performed factor
analysis via PEER on the inverse normalized FPKM (separately for genes, exons
and transcript isoforms; specifying from 1 to 100 factors; and including age, sex,
OGTT status, the top 2 genotype-based principal components and experimental
batch as covariates in the model, and (3) inverse normalized the resulting residuals.
We used the linear regression model with an additive genetic effect
Yij ¼ aþ bjsGis þ eij ð4Þ
where Gis is the imputed allele count for SNP s for individuals i, and bjs is the
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regression coefficient of the imputed allele count for SNP s on transformed gene
expression Yij.
We used FDR51 to account for multiple testing and considered as significant
associations with FDRr5%.
We present results based on 60 PEER factors since we expect that removing
technical and biological variation will increase power to detect cis-eQTLs and we
observed very little increase in the number of cis-eQTLs (FDRr5%) for 460
factors17 (Supplementary Fig. 22).
Comparison to GTEx skeletal musclegenic cis-eQTL results. We downloaded
the entire set of skeletal muscle SNP–gene association tests (V6) for 361 GTEx
skeletal muscle samples5 from the GTEx portal (www.gtexportal.org). We called
GTEx SNP–gene association tests with FDRr5% as significant. About 95,528,846
SNP–gene pairs (19,038 genes and 6,694,033 SNPs) were tested in common in the 2
studies and had concordant alleles. We oriented the association results in each
study to the same effect allele.
Genic cis-eQTL for GWAS variants for T2D and related traits. We compiled a
list of 225 GWAS variants for T2D, fasting glucose, fasting insulin and 2-h glucose,
each with and without adjustment for BMI, and for fasting proinsulin, from the
NHGRI GWAS catalogue61 and carried out manual curation of the literature to
create a comprehensive list that was up-to-date as of May 2014. We crossed this list of
225 GWAS variants with our list of gene-based cis-eQTL results, resulting in a total of
220 SNPs and 4,545 tested GWAS SNP–gene pairs. To identify GWAS variant cis-
eQTLs that are likely independent of other stronger cis-eQTLs for the same gene, and
to calculate a conditional-analysis-based FDR, we performed iterative conditional
analysis on each of the 4,545 SNP–gene pairs. For each such pair, we predicted Yij
(as defined for cis-eQTL analysis) starting with the GWAS SNP genotype in the
model, and then performed step-wise forward selection of SNPs within 1Mb of the
most upstream TSS, with a stopping threshold of a P value of 0.0019 (corresponding
to the P value threshold for gene-based cis-eQTLs with FDRo5%).
ASE measurements. Our goal was to quantify ASE at each protein-coding SNP.
Based on the calls from our DNA genotyping and imputation, for each individual
we identified all sites at which a SNP in a gencode V19 annotated protein-coding
exonic region was called as a heterozygote. At these sites, we quantified the
strand-specific read coverage using samtools mpileup (version 0.1.18) to process
the aligned RNA-seq read BAM files. We required a minimum mapping quality of
255, minimum base quality of 20 and reads mapped in a proper pair. We excluded
reads that failed vendor quality checks or that were not the primary alignment. ASE
was defined as the reference allele read count divided by referenceþ alternate read
count, termed fracRef.
ASE filtering to adjust for read mapping bias. We implemented multiple fil-
tering steps to identify and exclude SNPs susceptible to mapping errors that could
bias ASE quantification. To identify SNPs with mapping biases, we simulated reads
as previously described9, except we used 101 bp reads, and after mapping the
simulated reads excluded SNPs with a total simulated coverage of o193 and
4202. We excluded SNPs based on additional filters. Although mono-allelic
expression occurs at some sites, we required representation of both alleles in each
SNP per individual by requiring 0.01ofracRefo0.99. In addition, we excluded
SNPs in regions blacklisted by the ENCODE Project Consortium62 because of poor
mappability or the presence of collapsed repeat regions10. We excluded any SNP
within 101 bp of an indel greater than 4 bp or overlapping an indel of any length.
ASE statistical analysis. fracRef varies systematically by the reference and
alternate allele of the SNP. As previously described9, starting with the filtered SNP
list, for each sample, for each SNP reference and alternate allele pair (for example,
AG and GA are separate allele pairs), we estimated the expected fracRef. The
sample-specific and allele-pair-specific expected fracRef was calculated as the sum
of the reference allele counts divided by the sum of the total allele counts across all
SNP of a given reference and alternative pair for an individual. To prevent SNPs
with high coverage from biasing the estimated fracRef, SNPs with read count
coverage in the top 25th percentile were down-sampled to 30 coverage and the
down-sampled reference allele and total count were used. For each individual and
for each SNP, we performed a two-sided binomial test, using the observed sample-
specific or allele pair-specific fracRef as the true fracRef under the null hypothesis
of no ASE. Of the set of SNPs for each individual, we call ASE significant if the
Storey’s FDR q-valuer0.05. The forward and reverse stranded ASE quantifications
were combined after filters and before statistical analysis for accurate sample-
specific adjusted expectation calculation. To increase power to detect ASE, at each
SNP that meets the above thresholds and occured in Z10 samples, we combined
the binomial test P values using Fisher’s combined probability test.
Analysis of muscle-specific expression. We used an information theory
approach13,14 to score genes based on muscle expression level and specificity
relative to the panel of 16 diverse Illumina Human Body Map 2.0 tissues. We first
calculated expression (x) in FPKM values for all Gencode v19 genes across each of
the 16 tissues in the Body Map 2.0 data. We calculated the relative expression of
each gene (g) in skeletal muscle compared with all 16 tissues (t) as p:
pg;muscle ¼ xg;muscle=
X16
t¼1
xg;t ð5Þ
We next calculated the entropy for expression of each gene across all 16 tissues
as H:
Hg ¼ 
X16
t¼1
pg;t log2ðpg;tÞ ð6Þ
Following previous studies13,14, we defined muscle tissue expression specificity (Q)
for each gene as:
Qg;muscle ¼ Hg  log2ðpg;muscleÞ ð7Þ
To aid in interpretability, we divided Q for each gene by the maximum observed Q
and subtracted this value from 1 and refer to this new score as the mESI:
mESIg ¼ 1 QgQmax ð8Þ
mESI scores near zero represent low and/or ubiquitously expressed genes, and
scores near 1 represent genes that are highly and specifically expressed in skeletal
muscle. We note that although these calculations were performed using expression
measured by FPKM, we obtained similar results when using transcripts per million.
Chromatin state analyses. We performed read mapping and integrative chro-
matin state analyses as in our previous report15. Chromatin states were learned
jointly by applying the ChromHMM (version 1.10) hidden Markov model (HMM)
algorithm at 200 bp resolution to six data tracks (Input, K27ac, K27me3, K36me3,
K4me1, K4me3) from each of the cell or tissue types11. We collected cell or tissue
ChIP-seq reads from a diverse set of publically available data11,15,63,64 representing
31 cells/tissues. We ran ChromHMM with a range of possible states, and settled on
an 11-state model as it accurately captured information from higher state models
and provided sufficient resolution to identify biologically meaningful patterns in a
reproducible way. This process was similar to our previous analysis15. To
determine how our learned states relate to previously published states from nine
cell types11, we performed enrichment analyses comparing our states with the
published states in each cell type (Supplementary Fig. 6). We also performed gene
body feature overlaps, and TSS proximity analyses11. This process led to a clear
state assignment (Supplementary Fig. 6), which we used for all subsequent analyses.
We measured enrichment of cis-eQTLs at various levels of significance (FDR
thresholds of 5, 1 and 0.1%) to overlap chromatin states by retaining the single best
(lowest P value) cis-eQTL per gene, and using the GREGOR tool12 to calculate
enrichment relative to MAF, TSS-distance and number of LD neighbours-matched
null SNP sets. The enrichment trends were consistent across the different FDR
thresholds, with more stringent sets having slightly more pronounced trends. We
report here the results for the FDR¼ 0.1% set. We used the following GREGOR
parameters, which are what was reported in the original publication: r2
threshold¼ 0.8, LD window size¼ 1Mb and minimum neighbour number¼ 500.
ATAC-seq sample processing. ATAC-seq libraries were prepared using a
modified protocol based on previous studies20. Frozen human skeletal muscle
tissue (Zen-bio, Durham, NC USA) was cut into a 100-mg piece and disrupted
using liquid nitrogen and a CellCrusher (Cellcrusher, Cork Ireland). Nuclei were
isolated by placing disrupted tissue into ice cold nuclei isolation buffer (NIB)
(20mM Tris-HCl, 50mM EDTA, 5mM Spermidine, 0.15mM Spermine, 0.1%
mercaptoethanol, 40% Glycerol, pH 7.5). The solution was then filtered through a
Miracloth (Calbiochem, San Diego, CA USA) and centrifuged at 1,100g for 10min
at 4 C. The resultant nuclei pellet was washed with NIB containing 0.5% Triton-X
and RSB buffer (10mM Tris-HCl, 10mM NaCl, 3mM MgCl2, pH 7.4). The nuclei
pellet was resuspended in 50 ml RSB buffer, and 1:10 (10mg total tissue) and 1:50
(2mg total tissue) dilutions were made. The transposition reactions were
performed using a homemade Tn5 preparation (courtesy of the Jacob Kitzman
laboratory)20. The DNA was then purified using the Qiagen MinElute PCR
Purification kit (cat. No. 28004). Next, the libraries were PCR amplified to 9 cycles
for the 1:10 dilution and 11 cycles for the 1:50 dilution. A final clean-up was
performed with the Qiagen MinElute PCR Purification kit and samples were sent
to bioanalyzer for QC.
ATAC-seq analyses. We sequenced each ATAC-seq library to a depth of 448M
reads using a 50 bp paired-end read layout on an Illumina HiSeq. Adapter sequence
was trimmed from the raw ATAC-seq reads using a tool we developed based on the
one used in the original ATAC-seq paper20. Trimmed reads were then aligned to the
hg19 reference with BWA aln (http://bio-bwa.sourceforge.net/) version 0.7.12.
Duplicate alignments were marked with Picard Tools (https://broadinstitute.github.
io/picard/) version 1.131 and discarded for further analyses. We then filtered for
properly paired alignments and for reads uniquely mapped with high quality to
autosomal references, using samtools (https://samtools.github.io/) version 1.2 and
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flags ‘-f 3 -F 4 -F 8 -F 256 -F 1024 -F 2048 -q 30’. Finally, we called peaks using
MACS2 (https://github.com/taoliu/MACS/) version 2.1.0, with flags ‘-g hs --nomodel
--shift -100 --extsize 200 -B --broad --keep-dup all’ and retained peaks that met a 5%
FDR. For comparative purposes, we performed the same read trimming, alignment,
filtering and peak calling steps on publicly available ATAC-seq data in GM12878
(ref. 20) and adipose tissue21.
To detect potential TFBSs using both reference and alternate alleles, we
extracted the alternate allele from biallelic SNPs and short indels from 1000
Genomes phase 3 (release v5) along with 29 bp of flanking sequence from the hg19
human reference on each side. We scanned the reference and these extracted
alternate allele sequences with position weight matrixes (PWMs) from ENCODE65,
JASPAR66 and Jolma et al.67 using FIMO68. FIMO was run using nucleotide
frequencies from the hg19 reference (40.9% GC), and the default P value cutoff
(10 4).
ATAC-seq footprints were called using CENTIPEDE22. Briefly, for each PWM
scan result, we generated a strand-specific (relative to the motif orientation) 5-bp
resolution matrix encoding the number of Tn5 integration events in a
region±100 bp from each motif occurrence. We split the ATAC-seq signal into
three different categories based on the diverse fragment length distribution:
36–149 bp, 150–324 bp and 325–400 bp. A motif occurrence was considered bound
if the CENTIPEDE posterior probability was 40.99 and its coordinates were fully
contained within an ATAC-seq peak. We only considered footprints for motifs that
were significantly enriched in our data, using an enrichment approach as
previously described69.
Electrophoretic mobility shift assay. EMSAs were performed as previously
described70. Briefly, biotin-end-labelled complementary oligonucleotides were
designed (Integrated DNA Technologies, Coralville, IA USA) around the variant
rs508419 (50-AGGATAGG[T/C]GAGAGGCC-30). Nuclear protein extract from
human SkMC, myoblasts (HSMM) (Lonza, Walkersville, MD USA) and mouse
muscle myoblasts (C2C12) (ATCC, Manassas, VA USA) was prepared using the
NE-PER Extraction Kit (Thermo Scientific, Waltham, MA). The LightShift
Chemiluminescent EMSA Kit (Thermo Scientific) was used following the
manufacturer’s protocol with binding reactions comprising 1 binding buffer, 1
microgram poly(dI-dC), 6–10 mg nuclear extract and 400 fmol of labelled probe.
Reactions were incubated at room temperature for 30min. Competition reactions
had 25–40-fold excess of unlabelled oligonucleotides for either allele. For supershift
assays, 1.5–2 mg TR4 antibody (JD Engel Lab, University of Michigan) was added to
the reaction and incubated 30min at room temperature before addition of the
labelled probe. EMSAs were repeated and yielded comparable results.
Data availability. RNA-seq, ATAC-seq and genotype data for all samples used in
this paper have been deposited in dbGaP with the accession code phs001068.v1.p1
and are available via the repository’s data access request procedures.
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